Answers are grounded in this paper and cite their sources.
Disease clearance, proposed to be predictive of improved long-term outcomes, can be achieved in a clinically meaningful proportion of mild-to-moderate UC patients treated with mesalazine granules. A daily dose of 3.0 g appears optimal to reach this target.
No takes yet. Share an insight, caveat, or question.
Kruis et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: